![]() | David Matthew NathanThe Football Players Health Study at Harvard University, Boston, Massachusetts | Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA | Massachusetts ... |
KOL Resume for David Matthew Nathan (type 2, mellitus, diabetes type 2, diabetes, type)
Year | |
---|---|
2022 | The Football Players Health Study at Harvard University, Boston, Massachusetts |
2021 | Diabetes Center, Cardiovascular Performance Center, Massachusetts General Hospital, Boston, Massachusetts, USA. Massachusetts General Hospital, Harvard Medical School, Boston, MA |
2020 | Diabetes Research Center, Massachusetts General Hospital, Boston, MA. Massachusetts General Hospital and Harvard Medical School, Boston, MA |
2019 | Harvard Medical School, Boston, MA, USA Massachusetts General Hospital |
2018 | Diabetes Center and Clinical Research Center, Massachusetts General Hospital, Harvard Medical School, Bullfinch 55 Fruit Street, 02114, Boston, Massachusetts, USA Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (D.M.N.). |
2017 | Diabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Author affiliations are provided at the end of the article. Massachusetts General Hospital, Boston. |
2016 | Diabetes Center, Massachusetts General Hospital, and Harvard Medical School, Boston, MA Boston, Massachusetts |
2015 | Massachusetts General Hospital Diabetes Center Department of Medicine Boston Massachusetts USA |
2014 | Diabetes Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA General Medicine Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Harvard Medical School, Boston, USA |
2013 | 1, Diabetes Research Center, Massachusetts General Hospital and Harvard School of Medicine, Boston, Massachusetts Harvard Medical School Boston MA |
2012 | 6, Harvard Medical School, Boston, Massachusetts Harvard Medical School, Boston, MA, United States |
2011 | Diabetes Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA, USA |
2010 | Massachusetts General Hospital Diabetes Center, Boston, MA |
2009 | Corresponding Author: David M. Nathan, MD, MGH Diabetes Center, 50 Staniford St, Ste 340, Boston, MA 02114 From the Massachusetts General Hospital Diabetes Center, Boston, Massachusetts Harvard Medical School, Boston, MA 02115, USA |
Prominent publications by David Matthew Nathan
BACKGROUND: Effective prevention is needed to combat the worldwide epidemic of type 2 diabetes. We investigated the long-term extent of beneficial effects of lifestyle intervention and metformin on diabetes prevention, originally shown during the 3-year Diabetes Prevention Program (DPP), and assessed whether these interventions reduced diabetes-associated microvascular complications.
METHODS: The DPP (1996-2001) was a randomised trial comparing an intensive lifestyle intervention or ...
Known for Lifestyle Intervention | Microvascular Complications | Metformin Placebo | Dpp Outcomes Study | 15 Years |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
[ PUBLICATION ]
BACKGROUND: In the 2.8 years of the Diabetes Prevention Program (DPP) randomised clinical trial, diabetes incidence in high-risk adults was reduced by 58% with intensive lifestyle intervention and by 31% with metformin, compared with placebo. We investigated the persistence of these effects in the long term.
METHODS: All active DPP participants were eligible for continued follow-up. 2766 of 3150 (88%) enrolled for a median additional follow-up of 5.7 years (IQR 5.5-5.8). 910 participants ...
Known for Diabetes Incidence | Lifestyle Intervention Metformin | Weight Loss | 10 Years | Year Follow |
The Natural History of Progression From Normal Glucose Tolerance to Type 2 Diabetes in the Baltimore Longitudinal Study of Aging
[ PUBLICATION ]
The natural history of progression from normal glucose tolerance (NGT) to impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and type 2 diabetes is not well defined. We studied this progression using biennial oral glucose tolerance tests performed in the Baltimore Longitudinal Study of Aging and survival analysis to assess progression from NGT to abnormal fasting plasma glucose (FPG; > or =6.1 mmol/l), abnormal 2-h plasma glucose (2hPG; > or =7.8 mmol/l), IFG (FPG 6.1-6.9 ...
Known for Glucose Tolerance | Baltimore Longitudinal Study | 10 Years | Type 2 | Ifg Igt |
OBJECTIVE: This study investigated the long-term effects of intensive diabetic treatment on the progression of atherosclerosis, measured as common carotid artery intima-media thickness (IMT).
RESEARCH DESIGN AND METHODS: A total of 1,116 participants (52% men) in the Epidemiology of Diabetes Interventions and Complications (EDIC) trial, a long-term follow-up of the Diabetes Control and Complications Trial (DCCT), had carotid IMT measurements at EDIC years 1, 6, and 12. Mean age was 46 ...
Known for Complications Trial | Carotid Artery | Imt Progression | Diabetes Control | 12 Years |
Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) identify individuals at high risk for progression to diabetes. Whether IFG and IGT have comparable coronary heart disease (CHD) risk factor profiles, independent of their progression to diabetes, is unclear. We determined CHD risk factor levels in 937 nondiabetic individuals at baseline and biannually over a mean follow-up period of 9.5 years. Subjects had no known CHD at baseline and had > or =2 (mean 4.2) oral glucose ...
Known for Impaired Fasting Glucose | Ifg Igt | Baltimore Longitudinal Study | Chd Risk | Longitudinal Studies |
Association of the Magnitude of Weight Loss and Physical Fitness Change on Long-term CVD outcomes: The Look AHEAD Study
[ PUBLICATION ]
BACKGROUND: Findings from the Look AHEAD trial showed no significant reductions in the primary outcome of cardiovascular disease incidence in adults with type 2 diabetes randomly assigned to an intensive lifestyle intervention for weight loss compared with those randomly assigned to diabetes support and education (control). We examined whether the incidence of cardiovascular disease in Look AHEAD varied by changes in weight or fitness.
METHODS: Look AHEAD was a randomised clinical trial ...
Known for Weight Loss | Ahead Study | Cardiovascular Disease | Secondary Outcome | Physical Fitness |
Hyperinsulinemia, Hyperglycemia, and Impaired Hemostasis: The Framingham Offspring Study
[ PUBLICATION ]
CONTEXT: Increased risk for cardiovascular disease in persons with glucose intolerance (impaired glucose tolerance and type 2 diabetes mellitus) is not fully explained by concomitant elevations in traditional atherosclerosis risk factors. Hyperinsulinemia associated with glucose intolerance may increase risk directly, or its effect could be mediated through impaired hemostatic function.
OBJECTIVE: To evaluate associations between fasting insulin levels and hemostatic factors in subjects ...
Known for Glucose Intolerance | Hemostatic Factors | Impaired Hemostasis | Trend Levels | Offspring Study |
BACKGROUND: Clinical treatment goals of type 1 diabetes mellitus (T1DM) have changed since the Diabetes Control and Complications Trial (DCCT) demonstrated reduced long-term complications with intensive diabetes therapy. There have been few longitudinal studies to describe the clinical course of T1DM in the age of intensive therapy. Our objective was to describe the current-day clinical course of T1DM.
METHODS: An analysis of the cumulative incidence of long-term complications was ...
Known for Diabetes Complications | Pittsburgh Epidemiology | 30 Years | Patients T1dm | Intensive Therapy |
Intensive Diabetes Therapy and Carotid Intima–Media Thickness in Type 1 Diabetes Mellitus
[ PUBLICATION ]
BACKGROUND: Cardiovascular disease causes severe morbidity and mortality in type 1 diabetes, although the specific risk factors and whether chronic hyperglycemia has a role are unknown. We examined the progression of carotid intima-media thickness, a measure of atherosclerosis, in a population with type 1 diabetes.
METHODS: As part of the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the long-term follow-up of the Diabetes Control and Complications Trial (DCCT), ...
Known for Carotid Intima | Media Thickness | Intensive Diabetes | Type 1 | Risk Factors Progression |
Body Mass Index, Metabolic Syndrome, and Risk of Type 2 Diabetes or Cardiovascular Disease
[ PUBLICATION ]
CONTEXT: Metabolic risk conferred by adiposity may be due to associated risk factor clustering.
OBJECTIVE: The objective of this study was to assess risk for diabetes or cardiovascular disease (CVD) stratified by body mass index (BMI) and the presence or absence of metabolic syndrome (MetS) or insulin resistance (IR).
DESIGN, SETTING, AND PARTICIPANTS: This was a community-based, longitudinal study of 2902 people (55% women, mean age 53 yr) without diabetes or CVD in 1989-1992 followed ...
Known for Metabolic Syndrome | Risk Diabetes | Cardiovascular Disease | Mets Cvd | Type 2 |
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
[ PUBLICATION ]
BACKGROUND: Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle--are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes.
METHODS: We randomly assigned 3234 nondiabetic ...
Known for Lifestyle Intervention | Placebo Metformin | Type 2 | Incidence Diabetes | Elevated Fasting |
The Epidemiology of Diabetes Interventions and Complications (EDIC) study, an observational follow-up of the Diabetes Control and Complications Trial (DCCT) type 1 diabetes cohort, measured coronary artery calcification (CAC), an index of atherosclerosis, with computed tomography (CT) in 1,205 EDIC patients at approximately 7-9 years after the end of the DCCT. We examined the influence of the 6.5 years of prior conventional versus intensive diabetes treatment during the DCCT, as well as ...
Known for Diabetes Interventions | Coronary Artery Calcification | 1 Diabetic | Cac Dcct | Edic Study |
OBJECTIVE: High cholesterol levels in circulating immune complexes (IC), surrogate markers of modified LDL, are associated with increased carotid intima-media thickness (IMT) and cardiovascular events in type 1 diabetes. Different modifications of LDL are involved in IC formation, but which of these are predictive of vascular events is not known. Therefore, we measured oxidized LDL (oxLDL), advanced glycation end products-modified LDL (AGE-LDL), and malondialdehyde-modified LDL (MDA-LDL) ...
Known for Modified Ldl | Advanced Glycation | Type 1 Diabetes | Circulating Immune Complexes | Carotid Intima |
The common polymorphisms KCNJ11 E23K and ABCC8 A1369S have been consistently associated with type 2 diabetes. We examined whether these variants are also associated with progression from impaired glucose tolerance (IGT) to diabetes and responses to preventive interventions in the Diabetes Prevention Program. We genotyped both variants in 3,534 participants and performed Cox regression analysis using genotype, intervention, and their interactions as predictors of diabetes incidence over ...
Known for Diabetes Prevention Program | Type 2 | Insulin Secretion | Kcnj11 Abcc8 | Lysine Carriers |
David Matthew Nathan: Influence Statistics
Concept | World rank |
---|---|
a1c average glucose | #1 |
blood glucose analyses | #1 |
bmi microvascular complications | #1 |
moderate retinopathy risk | #1 |
outcome metformin | #1 |
development type diabetics | #1 |
mccarter hgi | #1 |
niddm decrements | #1 |
huis sf6d | #1 |
qol patient satisfaction | #1 |
retinal haemodynamics patients | #1 |
guardian aggregate mards | #1 |
subgroups small dose | #1 |
august expectation | #1 |
hba1c smbg values | #1 |
visual acuity tzd | #1 |
fbg levels indexes | #1 |
assessments retinal disease | #1 |
intensive therapy participants | #1 |
28 years metformin | #1 |
identical hba1c values | #1 |
specialists response rate | #1 |
t266 homozygotes association | #1 |
societies choose medications | #1 |
interindividual hba1c variations | #1 |
trait score | #1 |
dcct edic oxldl | #1 |
reduction cvd complications | #1 |
labile glycosylated | #1 |
reduction microvascular complications | #1 |
48hour pg values | #1 |
diabetes diabetologia 491711–1721 | #1 |
measurement glycated hemoglobin | #1 |
diabetes mellitus quality | #1 |
longitudinal cohort hba1c | #1 |
glucoscout | #1 |
826 adults | #1 |
risk diabetes complications | #1 |
edic intensive therapy | #1 |
conventional therapy progression | #1 |
large errors navigator | #1 |
dcct carotid | #1 |
retinopathy lower | #1 |
compelling new | #1 |
highcarbohydrate meals | #1 |
delayed gastrointestinal symptoms | #1 |
post meals | #1 |
mbg cvd | #1 |
a1c concentrations | #1 |
current evidence areas | #1 |
Open the FULL List in Excel | |
Key People For Type 2 Diabetes
David Matthew Nathan:Expert Impact
Concepts for whichDavid Matthew Nathanhas direct influence:Type 2 diabetes, Diabetes mellitus, 2 diabetes, Type 1 diabetes, Type 2, Insulin resistance, Cardiovascular disease, 1 diabetes.
David Matthew Nathan:KOL impact
Concepts related to the work of other authors for whichfor which David Matthew Nathan has influence:Type 2 diabetes, Metabolic syndrome, Insulin resistance, Weight loss, Glycemic control, Diabetic retinopathy, Blood glucose.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |